Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b studyJohn F. Seymour, Andrew W. Roberts, Jacqueline C. Barrientos et al.|The Lancet Oncology|2017Cited by 327
Pooled Multi-Trial Analysis of Venetoclax Efficacy in Patients with Relapsed or Refractory Chronic Lymphocytic LeukemiaAndrew W. Roberts, Michael Hallek, John F. Seymour et al.|Blood|2016Cited by 14